Valuation: CorMedix Inc.

Market Cap 566M 503M 466M 424M 800M 53.71B 813M 5.6B 2.2B 28.03B 2.12B 2.08B 89.34B P/E 2026 *
14.7x
P/E 2027 * 128x
Enterprise Value 456M 406M 376M 342M 646M 43.32B 656M 4.52B 1.77B 22.61B 1.71B 1.68B 72.07B EV / Sales 2026 *
1.35x
EV / Sales 2027 * 1.45x
Free-Float
92.39%
Yield 2026 *
-
Yield 2027 * -
1 day-2.68%
1 week-1.63%
Current month-5.71%
1 month-5.96%
3 months-13.78%
6 months-1.76%
Current year-37.58%
1 week 7.24
Extreme 7.235
7.7
1 month 7.06
Extreme 7.055
8.18
Current year 6.12
Extreme 6.125
12.29
1 year 6.12
Extreme 6.125
13.02
3 years 2.57
Extreme 2.57
17.43
5 years 2.57
Extreme 2.57
17.43
10 years 0.86
Extreme 0.8605
18.8
Manager TitleAgeSince
Chief Executive Officer 50 10/05/2022
Director of Finance/CFO 54 29/08/2025
Compliance Officer 66 12/12/2023
Director TitleAgeSince
Director/Board Member 67 06/08/2015
Chairman 81 03/08/2017
Director/Board Member 70 16/08/2011
Date Insider Type Main position Quantity % Market Cap. Importance
9/18/26 A Exercice

Director

97,818 0.1255%
8/29/26 A Tax

Chief Financial Officer

-8,424 0.0108%
8/29/26 A Tax

Compliance Officer

-8,424 0.0108%
Change 5-day change 1-year change 3-year change Capi.($)
-2.68%-1.63%-28.68%+121.34% 566M
+0.43%+6.59%+56.57%+107.01% 1,120B
+0.90%-2.25%+32.26%+67.33% 616B
+0.71%+3.24%+24.33%+91.20% 504B
-0.13%+5.98%+33.66%+52.01% 367B
+0.52%+0.24%+72.13%+43.10% 360B
-0.95%+4.70%+19.65%+43.09% 288B
-1.98%+3.73%-0.89%+17.28% 258B
-0.35%+4.25%+44.74%+52.51% 234B
-0.75%+3.32%+27.18%+96.05% 194B
Average -0.43%+2.82%+28.10%+69.09% 394.15B
Weighted average by Cap. +0.13%+3.52%+39.33%+73.52%

Financials

2026 *2027 *
Net sales 337M 300M 278M 253M 477M 31.99B 484M 3.34B 1.31B 16.69B 1.26B 1.24B 53.22B 289M 257M 238M 217M 409M 27.45B 416M 2.86B 1.12B 14.33B 1.09B 1.06B 45.67B
Net income 45.67M 40.59M 37.63M 34.23M 64.6M 4.33B 65.63M 452M 177M 2.26B 171M 168M 7.21B 5.33M 4.74M 4.39M 3.99M 7.54M 506M 7.66M 52.78M 20.69M 264M 20M 19.58M 841M
Net Debt -109M -97.26M -90.15M -82.02M -155M -10.38B -157M -1.08B -425M -5.42B -411M -402M -17.28B -147M -131M -121M -110M -208M -13.98B -212M -1.46B -572M -7.3B -553M -541M -23.26B
Projected Income Statement - Annual - CorMedix Inc.
Logo CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Employees
191
Date Price Change Volume
16/10/26 $7.260 -2.68% 1,140,589
15/10/26 $7.460 +0.95% 1,466,252
14/10/26 $7.390 0.00% 1,124,915
13/10/26 $7.390 -0.94% 1,415,670
12/10/26 $7.460 +1.08% 1,592,037
Trader
Investor
Global
Quality
-
ESG MSCI
BB
MarketScreener Ratings - CorMedix Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
7.260USD
Average target price
15.33USD
Spread / Average Target
+111.20%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - CorMedix Inc.
  1. Stock Market
  2. Stocks
  3. CRMD Stock